T1	PROC 1 20	Estudio comparativo
#1	AnnotatorNotes T1	C1579762; comparative study research; Research Activity
T2	CHEM 27 38	tobramicina
#2	AnnotatorNotes T2	C0040341; tobramycin; Organic Chemical · Antibiotic
T3	CHEM 41 52	tobramicina
#3	AnnotatorNotes T3	C0040341; tobramycin; Organic Chemical · Antibiotic
T4	CHEM 57 71	ciprofloxacino
#4	AnnotatorNotes T4	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T5	PROC 77 87	profilaxis
#5	AnnotatorNotes T5	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T6	PROC 96 127	biopsia transrectal de próstata
#6	AnnotatorNotes T6	C0401641; Transrectal biopsy of prostate; Diagnostic Procedure
T7	ANAT 119 127	próstata
#7	AnnotatorNotes T7	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T8	PROC 1441 1448	biopsia
#8	AnnotatorNotes T8	C0005558; Biopsy; Diagnostic Procedure
T9	PROC 155 174	Estudio de eficacia
#9	AnnotatorNotes T9	C1707887; Efficacy Study; Research Activity
T10	PROC 181 191	prevención
#10	AnnotatorNotes T10	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T11	PROC 227 258	biopsia transrectal de próstata
#11	AnnotatorNotes T11	C0401641; Transrectal biopsy of prostate; Diagnostic Procedure
T12	ANAT 250 258	próstata
#12	AnnotatorNotes T12	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T13	PROC 260 268	Revisión
#13	AnnotatorNotes T13	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T14	DISO 276 302	complicaciones infecciosas
#14	AnnotatorNotes T14	C0940933; infection as a complication; Disease or Syndrome
T15	PROC 353 387	Estudio prospectivo y aleatorizado
#15	AnnotatorNotes T15	C0033522; Prospective Studies; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
T16	PROC 434 454	biopsias de próstata
#16	AnnotatorNotes T16	C0194804; Biopsy of prostate; Diagnostic Procedure
T17	CHEM 493 504	tobramicina
#17	AnnotatorNotes T17	C0040341; tobramycin; Organic Chemical · Antibiotic
T18	PROC 557 564	biopsia
#18	AnnotatorNotes T18	C0005558; Biopsy; Diagnostic Procedure
T19	CHEM 679 690	tobramicina
#19	AnnotatorNotes T19	C0040341; tobramycin; Organic Chemical · Antibiotic
T20	CHEM 703 717	ciprofloxacino
#20	AnnotatorNotes T20	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T21	PROC 753 760	biopsia
#21	AnnotatorNotes T21	C0005558; Biopsy; Diagnostic Procedure
T22	PROC 870 878	biopsias
#22	AnnotatorNotes T22	C0005558; Biopsy; Diagnostic Procedure
T23	DISO 932 941	hematuria
#23	AnnotatorNotes T23	C0018965; Hematuria; Disease or Syndrome
T24	DISO 954 960	fiebre
#24	AnnotatorNotes T24	C0015967; Fever; Sign or Symptom
T25	DISO 972 983	hemospermia
#25	AnnotatorNotes T25	C0149707; Hemospermia; Finding
T26	ANAT 1000 1008	perineal
#26	AnnotatorNotes T26	C0031066; Anogenital region; Body Location or Region
T27	DISO 1021 1038	orquiepididimitis
#27	AnnotatorNotes T27	C0149881; Epididymo-orchitis; Disease or Syndrome
T28	DISO 1053 1071	retención urinaria
#28	AnnotatorNotes T28	C0080274; Urinary Retention; Finding
T29	DISO 1094 1100	fiebre
#29	AnnotatorNotes T29	C0015967; Fever; Sign or Symptom
T30	PROC 1152 1162	Ingresaron
#30	AnnotatorNotes T30	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T31	DISO 1167 1173	fiebre
#31	AnnotatorNotes T31	C0015967; Fever; Sign or Symptom
T32	PROC 1259 1271	hemocultivos
#32	AnnotatorNotes T32	C0200949; Blood culture; Laboratory Procedure
T33	PROC 1308 1326	pauta profiláctica
T34	CHEM 1342 1353	tobramicina
#33	AnnotatorNotes T34	C0040341; tobramycin; Organic Chemical · Antibiotic
T35	CHEM 1358 1372	ciprofloxacino
#34	AnnotatorNotes T35	C0008809; ciprofloxacin; Organic Chemical · Pharmacologic Substance
T36	PROC 1402 1412	prevención
#35	AnnotatorNotes T36	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T37	PROC 1416 1424	ingresos
#36	AnnotatorNotes T37	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T38	CHEM 1456 1467	tobramicina
#37	AnnotatorNotes T38	C0040341; tobramycin; Organic Chemical · Antibiotic
T39	DISO 1477 1489	complicación
#38	AnnotatorNotes T39	C0009566; Complication; Pathologic Function
T40	DISO 1511 1520	hematuria
#39	AnnotatorNotes T40	C0018965; Hematuria; Disease or Syndrome
T41	CHEM 1604 1627	amoxicilina-clavulánico
#40	AnnotatorNotes T41	C0054066; Amoxicillin / Clavulanate; Pharmacologic Substance
T42	CHEM 1629 1640	tobramicina
#41	AnnotatorNotes T42	C0040341; tobramycin; Organic Chemical · Antibiotic
T43	CHEM 1643 1679	cefalosporinas de tercera generación
#42	AnnotatorNotes T43	C0304320; Third generation cephalosporin; Organic Chemical · Antibiotic
T44	DISO 195 221	complicaciones infecciosas
#43	AnnotatorNotes T44	C0940933; infection as a complication; Disease or Syndrome
T45	ANAT 446 454	próstata
#44	AnnotatorNotes T45	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T46	DISO 994 1008	dolor perineal
#45	AnnotatorNotes T46	C0240717; Perineal pain; Sign or Symptom
T47	ANAT 1063 1071	urinaria
#46	AnnotatorNotes T47	C0042036; Urine; Body Substance
T48	DISO 1429 1435	fiebre
#47	AnnotatorNotes T48	C0015967; Fever; Sign or Symptom
T49	LIVB 305 319	microorganismo
#48	AnnotatorNotes T49	C0445623; Microorganism; Organism
T50	LIVB 395 404	pacientes
#49	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 471 480	pacientes
#50	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	Dose 505 521	100 mg una dosis
T54	Route 522 533	intravenosa
#51	AnnotatorNotes T54	C1522726; Intravenous Route of Drug Administration; Functional Concept
T55	Route 572 585	intramuscular
#52	AnnotatorNotes T55	C1556154; Intramuscular Route of Drug Administration; Functional Concept
T56	Duration 588 599	las 8 horas
T57	LIVB 637 646	pacientes
#53	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Route 718 722	oral
#54	AnnotatorNotes T58	C1527415; Oral Route of Drug administration; Functional Concept
T59	Dose 723 729	500 mg
T60	Dose 783 792	una dosis
T61	Frequency 793 806	cada 12 horas
T62	Duration 815 824	tres días
T63	LIVB 902 911	pacientes
#55	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	LIVB 1080 1089	pacientes
#56	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T65	LIVB 1185 1194	pacientes
#57	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	LIVB 1525 1539	microorganismo
#58	AnnotatorNotes T66	C0445623; Microorganism; Organism
T67	Duration 534 544	media hora
T68	Duration 730 740	media hora
T69	LIVB 1281 1288	E. Coli
#59	AnnotatorNotes T69	C0014834; Escherichia coli; Bacterium
T70	Date 1436 1448	post-biopsia
T71	LIVB 1563 1570	E. Coli
#60	AnnotatorNotes T71	C0014834; Escherichia coli; Bacterium
R1	Combined_with Arg1:T3 Arg2:T4	
R2	Used_for Arg1:T2 Arg2:T5	
R3	Used_for Arg1:T3 Arg2:T5	
R4	Location_of Arg1:T7 Arg2:T6	
R5	Before Arg1:T5 Arg2:T6	
R6	Before Arg1:T10 Arg2:T44	
R7	After Arg1:T44 Arg2:T11	
R8	Location_of Arg1:T12 Arg2:T11	
R9	Causes Arg1:T49 Arg2:T14	
R10	Experiences Arg1:T50 Arg2:T16	
R11	Location_of Arg1:T45 Arg2:T16	
R12	Experiences Arg1:T51 Arg2:T17	
R13	Has_Dose_or_Strength Arg1:T17 Arg2:T52	
R15	Has_Route_or_Mode Arg1:T17 Arg2:T54	
R16	Has_Duration_or_Interval Arg1:T17 Arg2:T67	
R17	Before Arg1:T17 Arg2:T18	
R18	Has_Route_or_Mode Arg1:T17 Arg2:T55	
R19	After Arg1:T17 Arg2:T56	
R20	Experiences Arg1:T51 Arg2:T18	
R21	Experiences Arg1:T57 Arg2:T19	
R22	Combined_with Arg1:T19 Arg2:T20	
R23	Has_Dose_or_Strength Arg1:T19 Arg2:T52	
R25	Has_Route_or_Mode Arg1:T19 Arg2:T54	
R26	Has_Duration_or_Interval Arg1:T19 Arg2:T67	
R27	Before Arg1:T19 Arg2:T21	
R28	Has_Route_or_Mode Arg1:T20 Arg2:T58	
R29	Has_Dose_or_Strength Arg1:T20 Arg2:T59	
R30	Has_Duration_or_Interval Arg1:T20 Arg2:T68	
R31	Before Arg1:T20 Arg2:T21	
R32	Has_Dose_or_Strength Arg1:T20 Arg2:T60	
R33	Has_Dose_or_Strength Arg1:T19 Arg2:T60	
R34	Before Arg1:T59 Arg2:T60	
R35	Before Arg1:T54 Arg2:T55	
R36	Has_Frequency Arg1:T20 Arg2:T61	
R37	Has_Frequency Arg1:T19 Arg2:T61	
R38	Has_Duration_or_Interval Arg1:T19 Arg2:T62	
R39	Has_Duration_or_Interval Arg1:T20 Arg2:T62	
R40	Experiences Arg1:T63 Arg2:T23	
R41	Experiences Arg1:T63 Arg2:T24	
R42	Experiences Arg1:T63 Arg2:T25	
R43	Experiences Arg1:T63 Arg2:T46	
R44	Location_of Arg1:T26 Arg2:T46	
R45	Experiences Arg1:T63 Arg2:T27	
R46	Location_of Arg1:T47 Arg2:T28	
R47	Experiences Arg1:T63 Arg2:T28	
R48	Experiences Arg1:T64 Arg2:T29	
R50	Experiences Arg1:T65 Arg2:T31	
R51	Experiences Arg1:T65 Arg2:T30	
R52	Overlap Arg1:T32 Arg2:T69	
R53	Used_for Arg1:T34 Arg2:T33	
R54	Combined_with Arg1:T34 Arg2:T35	
R55	Used_for Arg1:T34 Arg2:T36	
R56	Before Arg1:T36 Arg2:T48	
R58	Overlap Arg1:T48 Arg2:T70	
R59	Causes Arg1:T8 Arg2:T48	
R60	Used_for Arg1:T38 Arg2:T36	
R61	Used_for Arg1:T38 Arg2:T33	
T72	Quantifier_or_Qualifier 1468 1472	sola
R62	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T72	
T73	Quantifier_or_Qualifier 1571 1579;1602 1627	sensible a amoxicilina-clavulánico
R63	Has_Quantifier_or_Qualifier Arg1:T71 Arg2:T73	
T74	Quantifier_or_Qualifier 1571 1579;1602 1603;1629 1640	sensible a tobramicina
R64	Has_Quantifier_or_Qualifier Arg1:T71 Arg2:T74	
T75	Quantifier_or_Qualifier 1571 1579;1602 1603;1643 1679	sensible a cefalosporinas de tercera generación
R65	Before Arg1:T33 Arg2:T48	
R66	Has_Quantifier_or_Qualifier Arg1:T71 Arg2:T75	
R49	Before Arg1:T36 Arg2:T37	
#61	AnnotatorNotes T72	C0205171; Singular; Quantitative Concept
A1	Experiencer T50 Patient
A2	Experiencer T51 Patient
A3	Experiencer T57 Patient
A4	Experiencer T63 Patient
A5	Experiencer T64 Patient
A6	Experiencer T65 Patient
